Cancer drug developer Synthorx files for $100 million IPO

Synthorx, a La Jolla biotech developing cancer therapies from partly synthetic life, is seeking $100 million in an initial public offering.

The Scripps Research spinoff made the filing with the Securities and Exchange Commission on Tuesday. It seeks to trade on Nasdaq under the symbol THOR.